
20 Dec 2024
-22.7% looks weak, but what did we learn?

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
-22.7% looks weak, but what did we learn?
Novo Nordisk A/S Class B (NOVO.B:CSE) | 0 0 0.0%
- Published:
20 Dec 2024 -
Author:
ABGSC Healthcare Research | Morten Larsen -
Pages:
5 -